MeSH term
Frequency | Condition_Probility | Amyloid/*analysis | 6 | 17.0 |
Animals | 57 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
Female | 41 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Male | 42 | 0.0 |
Research Support, Non-U.S. Gov't | 78 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
Adult | 25 | 0.0 |
Humans | 92 | 0.0 |
Pregnancy | 4 | 0.0 |
Gene Expression | 3 | 0.0 |
Mice | 24 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Mice, Transgenic | 16 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Amino Acid Sequence | 26 | 0.0 |
Binding Sites | 5 | 0.0 |
Circular Dichroism | 6 | 1.0 |
Congo Red | 2 | 13.0 |
Microscopy, Electron | 14 | 0.0 |
Models, Molecular | 2 | 0.0 |
Molecular Sequence Data | 27 | 0.0 |
Spectroscopy, Fourier Transform Infrared | 2 | 4.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Comparative Study | 21 | 0.0 |
Insulin/metabolism | 3 | 2.0 |
Insulin Resistance | 3 | 1.0 |
Protein Conformation | 3 | 0.0 |
Protein Folding | 2 | 0.0 |
Species Specificity | 9 | 0.0 |
Amyloid/*metabolism | 6 | 11.0 |
Blood Glucose/metabolism | 11 | 1.0 |
Body Mass Index | 2 | 0.0 |
Insulin/blood | 8 | 1.0 |
Middle Aged | 23 | 0.0 |
Amyloid/*genetics | 9 | 25.0 |
Blotting, Northern | 4 | 0.0 |
Glucose/*pharmacology | 4 | 5.0 |
Diabetes Mellitus, Type 2/*metabolism | 4 | 8.0 |
Protein Binding | 4 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Islets of Langerhans/*metabolism/pathology | 2 | 40.0 |
Kinetics | 14 | 0.0 |
Sex Factors | 2 | 0.0 |
Time Factors | 8 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Rats | 25 | 0.0 |
Base Sequence | 10 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Mutation | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Amyloid/metabolism | 3 | 6.0 |
Cats | 9 | 2.0 |
Immune Sera/immunology | 3 | 1.0 |
Islets of Langerhans/*chemistry | 4 | 50.0 |
Rabbits | 2 | 0.0 |
Glucose Tolerance Test | 8 | 1.0 |
Insulin/analysis | 3 | 13.0 |
Islets of Langerhans/*metabolism | 4 | 7.0 |
Pancreas/chemistry | 2 | 8.0 |
English Abstract | 3 | 0.0 |
Insulin/secretion | 3 | 5.0 |
Glucose Clamp Technique | 3 | 2.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Somatostatin/analysis | 2 | 3.0 |
In Vitro | 3 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Diabetes Mellitus, Experimental/*metabolism | 2 | 11.0 |
Islets of Langerhans/*metabolism/ultrastructure | 3 | 75.0 |
Adolescent | 2 | 0.0 |
Aged | 19 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Amyloid/genetics | 2 | 15.0 |
Diabetes Mellitus, Type 2/pathology | 3 | 50.0 |
Haplorhini | 2 | 0.0 |
Aging/metabolism | 2 | 1.0 |
Amyloid/chemistry/*metabolism | 2 | 66.0 |
Amyloid/blood/genetics/*physiology | 2 | 100.0 |
Blood Glucose/*metabolism | 6 | 2.0 |
Fasting | 7 | 2.0 |
Insulin/blood/*secretion | 4 | 8.0 |
Blotting, Western | 2 | 0.0 |
Glucagon/*pharmacology | 2 | 18.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
C-Peptide/blood | 7 | 4.0 |
Creatinine/blood | 2 | 0.0 |
Radioimmunoassay | 9 | 0.0 |
Insulin/*secretion | 4 | 5.0 |
Chickens | 4 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Diabetes Complications | 2 | 1.0 |
Glucagon/pharmacology | 2 | 6.0 |
Islets of Langerhans/drug effects/*metabolism | 2 | 20.0 |
Dogs | 4 | 0.0 |
Guinea Pigs | 4 | 0.0 |
Hamsters | 5 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Placenta/metabolism | 2 | 1.0 |
*Glucose Tolerance Test | 3 | 5.0 |
Liver/metabolism | 4 | 0.0 |
Reference Values | 7 | 0.0 |
Regression Analysis | 2 | 0.0 |
Amyloid/*blood | 7 | 50.0 |
Infusions, Intravenous | 3 | 0.0 |
Kidney Failure, Chronic/*blood | 2 | 3.0 |
Binding, Competitive | 3 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Calcitonin Gene-Related Peptide/pharmacology | 2 | 6.0 |
Receptors, Calcitonin Gene-Related Peptide/*metabolism | 2 | 66.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Diabetes Mellitus, Type 2/*etiology/metabolism | 2 | 66.0 |
Islets of Langerhans/metabolism | 3 | 8.0 |
Diabetes Mellitus, Type 2/*metabolism/pathology | 2 | 28.0 |
Injections, Intravenous | 3 | 0.0 |
Amyloid/*pharmacology | 2 | 66.0 |
Calcitonin Gene-Related Peptide/*pharmacology | 2 | 15.0 |
Cattle | 2 | 0.0 |
Calcitonin Gene-Related Peptide/*metabolism | 2 | 15.0 |
Insulinoma/*metabolism | 2 | 50.0 |
Insulin/*blood | 2 | 1.0 |
Rats, Inbred Strains | 5 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 2 | 1.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Protein Precursors/*genetics | 2 | 1.0 |
*Chromosomes, Human, Pair 12 | 2 | 0.0 |
*Genes, Structural | 3 | 0.0 |
Calcitonin/genetics | 2 | 28.0 |
Calcitonin Gene-Related Peptide | 2 | 8.0 |
Gene Amplification | 2 | 0.0 |
Neuropeptides/genetics | 2 | 9.0 |
DNA/genetics | 2 | 0.0 |
Islets of Langerhans/*analysis | 2 | 50.0 |
